CPC Diagnostics launches first ICMR approved COVID-19 CLIA antibody test in India

Chennai, May 20, 2020 – CPC Diagnostics (‘CPC’), Chennai, a portfolio company of Everstone backed
healthcare platform Everlife Holdings Pte. Ltd (‘Everlife’), has launched SARS COV-2 IgM and SARS
COV-2 IgG tests in India. Both are CE-approved antibody tests and are the first of their kind to get
approved by the Indian Council of Medical Research (‘ICMR’).


The CLIA-based tests, developed by Shenzhen-based YHLO Biotech Co. Ltd, run on the fully-
automated analysers iFlash 1800/3000, offering sensitivity of 97.3% and 86.1% for IgG and IgM with
specificity of 96.3% and 99.2% respectively. The IgM assay is capable of detecting the disease as
early as the 7th day after infection. The iFlash system minimizes human error, while being able to
handle large volumes. Depending on the analyser model, a lab can report up to 1000 to 2000 results
per day on a single instrument, with the flexibility for facilities to add further modules to ramp up
output substantially.

CPC is also planning to launch another antibody testing solution that is ELISA-based, which is under
the process of ICMR approval. The ELISA tests developed by EUROIMMUN AG in Germany can be
programmed on any automated ELISA processor or ELISA reader in addition to the dedicated
EUROIMMUN analysers. These tests offer high sensitivity of 93.8% and 100% for IgG and IgA with
specificity of 99.3% and 90.5% respectively.


Antibody tests are very valuable in community screening and surveillance. They are a vital tool in
disease monitoring and they eminently complement the RT-PCR Tests. Unlike rapid tests which are
qualitative, CPC’s CLIA and ELISA tests provide semi-quantitative values. This feature is also useful to
assess the suitability of plasma (from individuals who have recovered) for therapy.


Commenting on the launch, R. Kailasnath, Managing Director, CPC Diagnostics, said “Our
government recognises the need for more and better testing, and we are happy to be contributing
to India’s fight against COVID-19 with these highly sensitive and specific assays. Our priority now is
to work closely with all stakeholders such as the government, the private sector as well as the
medical research fraternity to make these tests available to them.”


Raman Gandotra, CEO, Everlife, said “Everlife is committed to support its portfolio companies to
fight COVID-19 in all the countries where it operates, by providing safe and accurate testing of
COVID-19. Quantitative serological antibody testing is uniquely suited in the current COVID
environment where countries are not only looking at detecting and controlling the spread but also
preparing to re-open their economies.”


YHLO’s COVID-19 CLIA antibody tests have CE-IVD and Australian FSC certifications, and have been
exported to Australia, France, Germany and Italy.
EUROIMMUN’s COVID-19 ELISA antibody tests have CE-IVD certification and the IgG test has
received US FDA EUA approval. The tests are available in Germany, USA, Italy, Canada and Brazil.

CPC

About CPC Diagnostics


CPC is a Chennai based manufacturer and marketer of in-vitro diagnostic products. CPC has three
decades of experience in the industry and is well known for its pioneering efforts in introduction of
new products and technologies. With dedicated marketing sales and service teams, CPC operates in
India, Sri Lanka and Bangladesh.

For more information please visit CPC.

Everlife

About Everlife


Everlife Asia is a buy-and-build platform aimed to provide complete solutions for the healthcare and
research industries in South East Asia and India. As part of the Everstone Group, Everlife invests in
manufacturers and distributors in the region covering key strategic segments including in-vitro
diagnostics, medical diagnostics, critical care equipment, implants and consumables. Cure Capital is a
minority investor in Everlife. Everlife’s portfolio companies represent more than 200 principals and
its more than 600 employees operate in 7 countries.

For more information, visit Everlife Asia.


For Media Queries:
Karan Anand
[email protected]
+91 9833372732

Scroll to Top